|
|
|
|
|
Click Here to return To Results
|
|
|
|
Brain metastases (BMs) occur in 10% to 20% of adult patients with cancer, and with increased surveillance and improved systemic control, the incidence is likely to grow. Despite multimodal treatment, prognosis remains poor. Current evidence supports use of whole-brain radiation therapy when patients present with multiple BMs. However, its associated cognitive impairment is a major deterrent in patients likely to live longer than 6 months. In patients with oligometastases (one to three metastases) and even some with multiple lesions less than 3 to 4 cm, especially if the primary tumor is considered radiotherapy resistant, stereotactic radiosurgery is recommended; if the BMs are greater than 4cm, surgical resection with or without postoperative whole-brain radiation therapy should be considered. There is increasing evidence that systemic therapy, including targeted therapy and immunotherapy, is effective against BM and may be an early choice, especially in patients with sensitive primary tumors. In patients with progressive systemic disease, limited treatment options, and poor performance status, best supportive care may be appropriate. Regardless of treatment goals, use of corticosteroids or antiepileptic medications is helpful in symptomatic patients. In this review, we provide a summary of current therapy, as well as developments in the treatment of BM from solid tumors. |
|
(click to filter results - removes previous filter)
algorithm
anticoagulant,treatment
anticonvulsants
chemotherapy,CNS treatment and complications with
cognition
complications
immunotherapy
intellectual deficit
neoplasm,metastatic to CNS
neoplasm,metastatic to CNS-multiple
neoplasm,metastatic to CNS-prognosis of
neoplasm,metastatic to CNS-treatment of
prognosis
radiation therapy,CNS treatment and complications with
review article
stereotaxic surgery
steroid therapy,CNS treatment and complications with
treatment of neurologic disorder
|
Click Here to return To Results
|
|